Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

John Corboy to Demyelinating Diseases

This is a "connection" page, showing publications John Corboy has written about Demyelinating Diseases.

 
Connection Strength
 
 
 
0.311
 
  1. Hardy TA, Corboy JR, Weinshenker BG. Bal? concentric sclerosis evolving from apparent tumefactive demyelination. Neurology. 2017 05 30; 88(22):2150-2152.
    View in: PubMed
    Score: 0.140
  2. Simon JH, Zhang S, Laidlaw DH, Miller DE, Brown M, Corboy J, Bennett J. Identification of fibers at risk for degeneration by diffusion tractography in patients at high risk for MS after a clinically isolated syndrome. J Magn Reson Imaging. 2006 Nov; 24(5):983-8.
    View in: PubMed
    Score: 0.067
  3. Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, Filippi M. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol. 2006 Apr; 63(4):614-9.
    View in: PubMed
    Score: 0.065
  4. Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 02 12; 92(7):e723-e732.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)